A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)

OBJECTIVES: In the largest head-to-head comparison between an oral and an intravenous (IV) iron compound in patients with inflammatory bowel disease (IBD) so far, we strived to determine whether IV iron isomaltoside 1,000 is non-inferior to oral iron sulfate in the treatment of iron deficiency anemi...

Full description

Saved in:

Bibliographic Details
Main Authors:	Reinisch, Walter, Staun, Michael, Tandon, Rakesh K, Altorjay, Istvan, Thillainayagam, Andrew V, Gratzer, Cornelia, Nijhawan, Sandeep, Thomsen, Lars L
Format:	Artigo
Language:	Inglês
Published:	Nature Publishing Group 2013
Subjects:	Inflammatory Bowel Disease
Online Access:	https://ncbi.nlm.nih.gov/pmc/articles/PMC3853365/ https://ncbi.nlm.nih.gov/pubmed/24145678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/ajg.2013.335
Tags:	Add Tag No Tags, Be the first to tag this record!

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)

Similar Items